WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Options
Query Language
Stem
Sort by:
List Length
Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018085275) TARGETING LATS1/2 AND THE HIPPO INTRACELLULAR SIGNALING PATHWAY FOR CANCER IMMUNOTHERAPY
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/085275 International Application No.: PCT/US2017/059310
Publication Date: 11.05.2018 International Filing Date: 31.10.2017
IPC:
A61K 31/366 (2006.01) ,A61K 31/409 (2006.01) ,A61K 31/47 (2006.01) ,A61K 31/4725 (2006.01) ,A61K 31/497 (2006.01) ,A61K 39/00 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
335
having oxygen as the only ring hetero atom, e.g. fungichromin
365
Lactones
366
having six-membered rings, e.g. delta-lactones
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
40
having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
409
having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
47
Quinolines; Isoquinolines
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
435
having six-membered rings with one nitrogen as the only ring hetero atom
47
Quinolines; Isoquinolines
472
Non-condensed isoquinolines, e.g. papaverine
4725
containing further heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
4965
Non-condensed pyrazines
497
containing further heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
Applicants: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA[US/US]; 1111 Franklin Street 12th Floor Oakland, CA 94607-5200, US
Inventors: GUAN, Kun-Liang; US
MOROISHI, Toshiro; JP
Agent: WAHLSTEN, Jennifer, L.; US
HALIDAY, Emily, M.; US
WEAVER, Jeffrey, K.; US
AUSTIN, James, E.; US
VILLENEUVE, Joseph, M.; US
SAMPSON, Roger, S.; US
GRIFFITH, John, F.; US
BERGIN, Denise, S.; US
SCHOLZ, Christian, D.; US
Priority Data:
62/416,41402.11.2016US
Title (EN) TARGETING LATS1/2 AND THE HIPPO INTRACELLULAR SIGNALING PATHWAY FOR CANCER IMMUNOTHERAPY
(FR) CIBLAGE DE LATS1/2 ET DE LA VOIE DE SIGNALISATION INTRACELLULAIRE HIPPO POUR IMMUNOTHÉRAPIE ANTICANCÉREUSE
Abstract:
(EN) Provided are tumor cells having reduced or eliminated expression and/or activity of one or more proteins within or associated with the HIPPO intracellular signaling selected from the group consisting of large tumor suppressor kinase 1 (LATS1), large tumor suppressor kinase 2 (LATS2), serine/threonine kinase 4 (STK4) and a MAP4K family kinase (e.g., MAP4K1/2/3/4/5/6/7), as well as extracellular vesicles and cell lysates from such tumor cells. The tumor cells may also have reduced or eliminated expression and/or activity of serine/threonine kinase 3 (STK3) and/or overexpress one or both of YAP and/or TAZ, or hyperactive mutants thereof. Further provided are methods of inducing, promoting and/or enhancing an immune response against a tumor in a subject by administering tumor cells having reduced or eliminated expression and/or activity of one or more proteins within or associated with the HIPPO intracellular signaling selected from the group consisting of large tumor suppressor kinase 1 (LATS1), large tumor suppressor kinase 2 (LATS2), serine/threonine kinase 4 (STK4) and a MAP4K family kinase (e.g., MAP4K1/2/3/4/5/6/7), or extracellular vesicles or cell lysates of such tumor cells. Further provided are methods of inducing, promoting and/or enhancing an immune response against a tumor in a subject by administering inhibitors of expression and/or activity of one or more proteins within or associated with the HIPPO intracellular signaling selected from the group consisting of large tumor suppressor kinase 1 (LATS1), large tumor suppressor kinase 2 (LATS2), serine/threonine kinase 4 (STK4) and a MAP4K family kinase (e.g., MAP4K1/2/3/4/5/6/7), and optionally further inhibiting the expression and/or activity of serine/threonine kinase 3 (STK3).
(FR) La présente invention concerne des cellules tumorales ayant une expression et/ou une activité réduite ou éliminée d’une ou plusieurs protéines dans ou associées à la signalisation intracellulaire HIPPO choisies dans le groupe constitué de la grande kinase suppresseur de tumeur 1 (LATS1), la grande kinase suppresseur de tumeur 2 (LATS2), la sérine/thréonine kinase 4 (STK4) et une kinase de la famille MAP4K (par exemple, MAP4K1/2/3/4/5/6 /7), ainsi que des vésicules extracellulaires et des lysats cellulaires de telles cellules tumorales. Les cellules tumorales peuvent également avoir une expression et/ou une activité réduite ou éliminée de la sérine/thréonine kinase 3 (STK3) et/ou surexprimer l’un ou les deux parmi YAP et/ou TAZ, ou des mutants hyperactifs de ceux-ci. L’invention concerne en outre des procédés d’induction, de promotion et/ou d’amélioration d’une réponse immunitaire contre une tumeur chez un sujet par administration de cellules tumorales ayant une expression et/ou activité réduite ou éliminée d’une ou plusieurs protéines dans ou associées à la signalisation intracellulaire HIPPO choisies dans le groupe constitué de la grande kinase suppresseur de tumeur 1 (LATS1), la grande kinase suppresseur de tumeur 2 (LATS2), la sérine/thréonine kinase 4 (STK4) et une kinase de la famille MAP4K (par exemple, MAP4K1/2/3/4/5/6/7), ou des vésicules extracellulaires ou des lysats cellulaires de telles cellules tumorales. L’invention concerne en outre des procédés d’induction, promotion et/ou amélioration d’une réponse immunitaire contre une tumeur chez un sujet par administration d’inhibiteurs d’expression et/ou d’activité d’une ou plusieurs protéines dans ou associées à la signalisation intracellulaire HIPPO choisies dans le groupe constitué de la grande kinase suppresseur de tumeur 1 (LATS1), la grande kinase suppresseur de tumeur 2 (LATS2), la sérine/thréonine kinase 4 (STK4) et la kinase de la famille MAP4K (par exemple, MAP4K1/2/3/4/5/6/7), et facultativement en outre inhiber l’expression et/ou l’activité de la sérine/thréonine kinase 3 (STK3).
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)